{"id":125998,"date":"2026-09-04T15:05:19","date_gmt":"2026-09-04T15:05:19","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/125998\/"},"modified":"2026-09-04T15:05:19","modified_gmt":"2026-09-04T15:05:19","slug":"neil-jones-and-phil-masterson-the-charity-model-behind-a-1-5b-novartis-deal-biggo-finance","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/125998\/","title":{"rendered":"Neil Jones and Phil Masterson: The Charity Model Behind a $1.5B Novartis Deal \u2014 BigGo Finance"},"content":{"rendered":"<p>The news that Novartis agreed to pay up to $1.5 billion for a little-known British biotech called MyRix Bio in 2026 didn&#8217;t just produce a win for its venture backers. It validated an unusual model that has been quietly taking shape: a medical charity acting not just as a funder of early science, but as a full participant in the commercial life of a drug company. According to Neil Jones, VP of Portfolio Generation, and Phil Masterson, Associate Director of Ventures at Cancer Research Horizons, speaking on the Proof of Concept podcast, the MyRix Bio exit is the first from the charity&#8217;s own seed fund \u2014 and it may be a template for how non-profits can recycle returns into more research.<\/p>\n<p>The significance goes beyond one deal. Cancer Research Horizons is the innovation arm of Cancer Research UK (CRUK), an organization that spends billions on medical research each year. For decades, the model was straightforward: fund academic labs, license out any resulting intellectual property, and hope for modest royalties. What Jones and Masterson describe is something far more deliberate. The charity now builds companies, writes seed checks, negotiates licensing terms, and works directly with pharma partners like AstraZeneca and Forma Therapeutics. It is, in effect, running a venture capital operation with a non-profit mandate.<\/p>\n<p>The Three Levers Behind a $1.5 Billion Exit<\/p>\n<p>The MyRix Bio story is the clearest illustration of how this works in practice. Masterson walks through the three distinct ways Cancer Research Horizons contributed to the company&#8217;s eventual acquisition by Novartis.<\/p>\n<p>First, CRUK funded the laboratory of Ed Tate at Imperial College London. The intellectual property generated there \u2014 though only a small part of the final IP package licensed into MyRix \u2014 was foundational to the company&#8217;s formation. Second, as MyRix approached its Series A round, which would become one of the largest in Europe at \u00a390 million in July 2024, the company needed bridge financing to buy time during negotiations with lead investors. Cancer Research Horizons deployed capital from its seed fund at precisely that moment. Third, the company went on to be acquired by Novartis.<\/p>\n<p>Masterson frames the outcome not primarily as a financial win but as an acceleration of the technology into a valuable clinical space. Yet the financial mechanics matter too. &#8220;We are both a licensor of IP and an investor in this company. And, you know, critically, that will see returns back to the charity that can be recycled into further research,&#8221; he noted. &#8220;But ultimately, the big event here is a great outcome for the company and an acceleration of that technology in a very valuable space.&#8221;<\/p>\n<p>The structure of this deal \u2014 charity-funded science, charity seed investment, private Series A, pharma acquisition \u2014 illustrates the full arc of the model. Returns flow back to CRUK and are recycled into the next generation of research, creating what Jones later calls a &#8220;virtuous circle.&#8221; The charity&#8217;s contribution was not a passive grant but a series of timed interventions at critical moments of the company&#8217;s development.<\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/09\/7425526c0b8a7258_1788511264_inline_1.jpg\" alt=\"\"\/><\/p>\n<p>Where Charities Invest When the Market Won&#8217;t<\/p>\n<p>The core investment philosophy at Cancer Research Horizons, as Jones describes it, is to identify unmet patient need where pharma and biotech either cannot or will not operate. The flagship example is the See Further initiative for childhood cancer, a collaboration with other charities including Life Arc and Great Ormond Street Hospital Charity.<\/p>\n<p>Childhood cancer is an area of profound unmet need but weak commercial incentives. The patient populations are too small to justify the development costs pharma would incur. For a charity, the calculus is different. The success metric is patient impact, not quarterly returns. &#8220;We can perhaps take a few more risks and work in spaces where they perhaps don&#8217;t want to commit to at this moment,&#8221; Jones said.<\/p>\n<p>Investment AreaCommercial ViabilityCharity RationaleChildhood cancer (See Further)Low \u2014 small patient populationsHigh unmet need; &#8220;child-first&#8221; drug discovery approachDeubiquitinase targets (with Forma Therapeutics)Moderate \u2014 novel target classAcademic network + in-house capability + partner chemistryDistressed pharma assets (Ionctura)Moderate \u2014 repurposing riskIn-house immuno-oncology expertise to reposition assets<\/p>\n<p>The Ionctura example is particularly instructive. Cancer Research Horizons took a PI3 kinase delta inhibitor and an autotaxin inhibitor \u2014 assets that had stalled in other hands \u2014 and used its internal capabilities to reposition them for cancer indications, driving them toward clinical trials and securing further investment. This is a form of arbitrage: the charity can see value in assets the market has written off because its success metric is patient impact, not quarterly returns.<\/p>\n<p>Masterson adds a critical caveat from the ventures perspective. While the charity can take higher risk and go earlier than traditional investors, the quality bar must remain equally high. The logic is unforgiving \u2014 if Cancer Research Horizons invests in something that cannot attract subsequent financing, the investment is wasted regardless of scientific merit. &#8220;There is no point in us investing in something that gets an opportunity to a point where it can&#8217;t attract more funding. That&#8217;s just a waste of time,&#8221; he said.<\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/09\/7425526c0b8a7258_1788511348_inline_2.jpg\" alt=\"\"\/><\/p>\n<p>The Circle of Risk: A Framework, Not a Checklist<\/p>\n<p>Masterson articulates a clear framework for how the ventures team evaluates early-stage opportunities. He describes it as a &#8220;circle of risk&#8221; with four components: the technology itself, the market for that technology, the strategy for development, and the intellectual property position. The fifth element \u2014 the team \u2014 is what binds the circle together.<\/p>\n<p>The framework is notable for what it does not require: perfection. &#8220;You don&#8217;t have to have ticked every box completely, because no opportunity arrives with you like that, but you need to be able to articulate very clearly where those risks are, how they will be addressed, and where along the timeline this will happen,&#8221; Masterson said.<\/p>\n<p>The current market context sharpens these requirements. Masterson notes that pharma faces a massive patent cliff and needs to repopulate pipelines, but they increasingly prefer later-stage assets with clinical data. Meanwhile, the innovation landscape is vast and competitive \u2014 pharma has enormous choice. Early-stage companies must demonstrate genuinely differentiated biology and operational discipline: knowing where they are, where they want to go, what it costs, and how long it takes.<\/p>\n<p>The Patent Timing Question<\/p>\n<p>A significant portion of the discussion addresses intellectual property strategy and the decision of when to form a company. Jones explains that the instinct is often to patent late rather than early \u2014 extending patent life at the commercial end of the timeline. But this must be balanced against the academic imperative to publish. Researchers in the CRUK network need freedom to publish their findings, which can force earlier patent filings than commercial strategy alone would dictate.<\/p>\n<p>&#8220;We usually have a strategy to not partner too early, not patent too early in most scenarios, because obviously then you can extend the patent life at the other end. But it&#8217;s always got to do with the science behind it,&#8221; Jones said.<\/p>\n<p>Masterson&#8217;s guidance on spin-out timing is equally specific: don&#8217;t spin out too early. Cancer Research Horizons can deploy capital to fund key experiments and decision-making science while the work remains inside the academic institution. The company formation happens at the point where significant external finance must be raised or a team must be built and compensated \u2014 administrative overhead that should not be carried prematurely.<\/p>\n<p>The shift from licensing to ventures as the primary commercialization route reflects broader market dynamics. Masterson attributes this to pharma&#8217;s patent cliff and preference for later-stage assets, which makes licensing early-stage science less attractive. But Jones adds a cultural dimension: academic researchers increasingly want to stay involved with their projects longer and maintain a stake in the outcomes. Cancer Research Horizons has responded with entrepreneurial training and mentorship programs, noting that the UK has historically lagged the US in this mindset shift.<\/p>\n<p>What Pharma Can Expect from a Charity Partner<\/p>\n<p>For pharma companies considering engagement with Cancer Research Horizons, the episode outlines several distinct partnership models. Jones describes the spectrum: large-scale alliances such as the past collaboration with AstraZeneca, focused partnerships like the multi-year work with US biotech Forma Therapeutics on deubiquitinase targets, and spin-out vehicles like Ionctura that repurpose distressed assets.<\/p>\n<p>Masterson emphasizes that pharma serves multiple roles in the ventures ecosystem. They are potential acquirers of portfolio companies, so Cancer Research Horizons invests heavily in understanding what pharma is looking for and building networks of key individuals. They are also potential strategic partners for early-stage companies, providing validation and non-dilutive capital. And their corporate venture arms represent an additional funding stream for portfolio companies navigating a challenging fundraising environment.<\/p>\n<p>The partnership logic is mutual: charities bring academic networks, in-house drug discovery capabilities, and the ability to take risks on scientifically promising but commercially uncertain projects. Pharma brings chemistry expertise, development infrastructure, regulatory pathways, and ultimately the distribution channels to reach patients.<\/p>\n<p>Who Gets the Upside: The Value Distribution Question<\/p>\n<p>The host raises a pointed question about the ethics and economics of charity-funded science generating blockbuster profits for private companies. Both guests acknowledge the tension but frame it as a necessary feature of the ecosystem rather than a flaw.<\/p>\n<p>The argument is pragmatic: charities cannot take drugs to clinic alone. The path from discovery to patient is enormously time-consuming and costly, with attrition rates that make the endeavor financially prohibitive for non-profits. The ecosystem must work in step, with each participant receiving a fair financial return proportional to their contribution. Masterson argues that the shift toward venture creation \u2014 rather than simple licensing \u2014 actually improves the value distribution, because the company structure and subsequent acquisition present a cleaner mechanism for ensuring the charity&#8217;s contribution is properly valued.<\/p>\n<p>The circularity is the point. Returns from successful exits are recycled into the next generation of research, funding the science that will produce the next spin-out. Jones emphasizes that this virtuous circle is only possible because charities have different drivers than commercial entities \u2014 the fundamental objective is getting treatments to patients as quickly as possible, and financial returns are a means to that end, not the end itself.<\/p>\n<p>The Charity as Ecosystem Convener<\/p>\n<p>Across the episode, a consistent picture emerges of Cancer Research Horizons as less a funder and more a convener \u2014 the entity that holds the ecosystem together. The charity sits at the intersection of academic researchers (who need publication freedom and career advancement), pharma companies (who need pipeline assets and acquisition targets), VC investors (who need de-risked opportunities), and patients (who need treatments). Its non-profit status gives it a credibility and neutrality that no commercial actor can match, while its in-house drug discovery capabilities give it technical credibility that pure funders lack.<\/p>\n<p>The unresolved tension in the model is scale. The MyRix Bio exit is celebrated as validation, but it is one data point. The episode does not disclose the fund&#8217;s overall performance, hit rate, or average returns. The model&#8217;s sustainability depends on whether exits like this occur with sufficient frequency to fund the next generation of research \u2014 and whether the increasing competition for early-stage deals, the patent cliff dynamics, and the shift toward later-stage pharma acquisitions continue to favor the charity&#8217;s approach.<\/p>\n<p>What is worth watching: whether the See Further childhood cancer initiative produces assets that attract commercial partners despite the challenging economics; whether the UK&#8217;s academic entrepreneurship culture continues to converge with the US model; and whether the MyRix Bio outcome catalyzes more pharma companies to view charity-backed ventures as attractive acquisition targets. Cancer Research Horizons is no longer a passive grant-maker \u2014 it is an active, risk-taking participant in the commercial life sciences ecosystem, and its model may offer a template for how non-profits can translate science into medicine far beyond their weight class.<\/p>\n","protected":false},"excerpt":{"rendered":"The news that Novartis agreed to pay up to $1.5 billion for a little-known British biotech called MyRix&hellip;\n","protected":false},"author":2,"featured_media":125999,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[14607,48647,48674,61476,61473,61478,48773,61474,61477,61470,61471,206,61472,61475],"class_list":["post-125998","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-astrazeneca","tag-cancer-research-horizons","tag-cancer-research-uk","tag-ed-tate","tag-forma-therapeutics","tag-great-ormond-street-hospital-charity","tag-imperial-college-london","tag-ionctura","tag-life-arc","tag-myrix-bio","tag-neil-jones","tag-novartis","tag-phil-masterson","tag-see-further-initiative"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117213392112476700","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/125998","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=125998"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/125998\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/125999"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=125998"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=125998"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=125998"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}